HIF1A and neoplasm: Another study in a mouse model and clinical samples established that HIF-1α is a potent inhibitor of nuclear factor kappa B (NF-κB) signaling driven by interleukin (IL)-18 and the antitumor activity of tumor-infiltrating NK cells and, therefore, represents a potential immunotherapy target (14).